Macrogenics MGNX

MacroGenics Inc is a clinical stage biopharmaceutical company focused on developing innovative antibody based therapeutics for the treatment of cancer. The company generates its pipeline from proprietary antibody technology platforms including DART and TRIDENT molecules and antibody drug conjugates. It operates a commercial scale cGMP manufacturing facility in Rockville Maryland that supports its clinical programs and provides contract development and manufacturing services to collaborators and third parties. MacroGenics also pursues preclinical programs that explore next generation T cell engager designs and novel linker payload combinations to expand its therapeutic reach across solid tumors and hematologic malignancies.

The company generates revenue from sales of its approved products ZYNYZ TZIELD and MARGENZA from royalties and milestone payments under collaboration agreements from up front payments and from contract development and manufacturing services provided to partners such as Incyte Emergent BioSolutions and TerSera. In addition MacroGenics receives option exercise payments and research funding from partners like Gilead under agreements that include potential future milestone and royalty streams. These arrangements have provided the company with over $1.6 billion of non dilutive funding since its inception in 2000. The company also offsets facility operating costs by offering manufacturing capacity to third parties which contributes to recurring service revenue.

MacroGenics occupies a niche in the oncology biotechnology sector as a developer of antibody based therapeutics that leverage its proprietary DART and TRIDENT platforms to create multi specific molecules. The company competes with large pharmaceutical and biotechnology firms such as AstraZeneca Genmab Merck Pfizer and AbbVie that have greater financial and manufacturing resources. Its competitive advantages include its innovative platform technologies its integrated cGMP manufacturing capability and its ability to secure non dilutive funding through strategic collaborations. MacroGenics also benefits from a diversified pipeline that spans multiple therapeutic modalities and from its track record of delivering three FDA approved product candidates derived from its own research.

The company serves a diverse customer base that includes biopharmaceutical partners such as Incyte for manufacturing services Gilead for collaborative drug development TerSera which acquired global rights to MARGENZA Emergent BioSolutions for contract manufacturing and Sagard Healthcare Partners which purchased a royalty interest in ZYNYZ. Additionally MacroGenics works with hospitals and clinics that administer its approved therapies to patients and with distributors that supply its products to healthcare providers. Patients and healthcare providers benefit from the company's approved therapies.